From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

sanfetrinem cilexetil   Click here for help

GtoPdb Ligand ID: 13812

Synonyms: GV118819
Compound class: Synthetic organic
Comment: Sanfetrinem cilexetil is the orally bioavailable prodrug of sanfetrinem [1]. It is under clinical development as a treatment for tuberculosis (TB).

sanfetrinem cilexetil is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 111.6
Molecular weight 451.51
XLogP 2.69
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES C[C@H]([C@@H]1[C@H]2[C@H]3CCC[C@@H](C3=C(C(=O)OC(C)OC(=O)OC4CCCCC4)N2C1=O)OC)O
Isomeric SMILES C[C@H]([C@@H]1[C@H]2[C@H]3CCC[C@@H](C3=C(N2C1=O)C(=O)OC(C)OC(=O)OC4CCCCC4)OC)O
InChI InChI=1S/C23H33NO8/c1-12(25)17-19-15-10-7-11-16(29-3)18(15)20(24(19)21(17)26)22(27)30-13(2)31-23(28)32-14-8-5-4-6-9-14/h12-17,19,25H,4-11H2,1-3H3/t12-,13?,15+,16+,17-,19-/m1/s1
InChI Key QFEICXCLIGZEJB-IRVPUMQPSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Sanfetrinem cilexetil was developed by GlaxoSmithKline in the 1990s and progressed to clinical evaluation as a treatment for bacterial infections of the upper respiratory tract. Its development was halted based on commercial considerations. More recently, drug repurposing efforts have identified the potential of sanfetrinem cilexetil as a treatment for TB [2]. The drug has completed a Phase 2 trial to evaluate safety, tolerability, pharmacokinetics, and early bactericidal activity (EBA) in adult participants with rifampicin-sensitive pulmonary TB (NCT05388448).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05388448 EBA, Safety and Tolerability of Sanfetrinem Cilexetil Phase 2 Interventional TASK Applied Science